Membrane‐bound CD200 is overexpressed in chronic lymphocytic leukemia (CLL), and there is some evidence that its soluble ectodomain (sCD200) could also be involved in the pathophysiology and the disease. However, very little is known about sCD200’s prognostic significance. sCD200 was tested at diagnosis in 272 patients with CLL and in 78 age‐ and sex-matched healthy subjects using a specific human CD200 (OX‐2 membrane glycoprotein) ELISA kit. A significantly higher concentration of sCD200 was found in CLL patients compared to controls. In our cohort, sCD200 was significantly higher in patients who were older than 66 years, with Binet stage C, unmutated IgVH and unfavorable (del11q or del17p) FISH. Time‐to‐first treatment and overall survival were significantly shorter in patients with higher sCD200 concentration, using as a cut‐off 1281 pg/mL, the median value for sCD200 concentration in the whole CLL cohort. However, the prognostic impact of sCD200 was not confirmed in multivariate analysis. Baseline sCD200 values appeared to have an impact on the response to chemotherapy or chemo‐immunotherapy, but not to targeted agents. Collectively, our data show that sCD200 serum levels correlate with more aggressive clinical and biological features and are able to predict a worse prognosis. This work supports the relevant role of CD200 not only as a diagnostic tool but also as a prognostic indicator and a potential therapeutic target in CLL.

Cd200 baseline serum levels predict prognosis of chronic lymphocytic leukemia

Vitale C.;Coscia M.;Perutelli F.;Griggio V.;Jones R.;
2021

Abstract

Membrane‐bound CD200 is overexpressed in chronic lymphocytic leukemia (CLL), and there is some evidence that its soluble ectodomain (sCD200) could also be involved in the pathophysiology and the disease. However, very little is known about sCD200’s prognostic significance. sCD200 was tested at diagnosis in 272 patients with CLL and in 78 age‐ and sex-matched healthy subjects using a specific human CD200 (OX‐2 membrane glycoprotein) ELISA kit. A significantly higher concentration of sCD200 was found in CLL patients compared to controls. In our cohort, sCD200 was significantly higher in patients who were older than 66 years, with Binet stage C, unmutated IgVH and unfavorable (del11q or del17p) FISH. Time‐to‐first treatment and overall survival were significantly shorter in patients with higher sCD200 concentration, using as a cut‐off 1281 pg/mL, the median value for sCD200 concentration in the whole CLL cohort. However, the prognostic impact of sCD200 was not confirmed in multivariate analysis. Baseline sCD200 values appeared to have an impact on the response to chemotherapy or chemo‐immunotherapy, but not to targeted agents. Collectively, our data show that sCD200 serum levels correlate with more aggressive clinical and biological features and are able to predict a worse prognosis. This work supports the relevant role of CD200 not only as a diagnostic tool but also as a prognostic indicator and a potential therapeutic target in CLL.
13
4239
1
9
CD200; Chronic lymphocytic leukemia; Prognosis; Serum
D'arena G.; Vitale C.; Coscia M.; Lamorte D.; Pietrantuono G.; Perutelli F.; D'auria F.; Statuto T.; Valvano L.; Tomasso A.; Griggio V.; Jones R.; Mansueto G.; Villani O.; D'agostino S.; Viglioglia V.; De Feo V.; Calapai F.; Mannucci C.; Sgambato A.; Efremov D.G.; Laurenti L.
File in questo prodotto:
File Dimensione Formato  
cancers-13-04239-v2.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 820.61 kB
Formato Adobe PDF
820.61 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1800958
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact